Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 23 hours ago

Indications

For rheumatoid arthritis, Filgotin is used in adults with moderate to severe active disease who have not responded well enough to one or more disease-modifying anti-rheumatic drugs (DMARDs), or who can't tolerate them. It can be taken on its own as monotherapy or together with methotrexate (MTX). For ulcerative colitis, Filgotin is used in adults with moderately to severely active disease. This applies to people who had an inadequate response to either conventional therapy or a biologic agent, lost response to it, or could not tolerate it.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Filgotinib is an adenosine triphosphate (ATP)-competitive and reversible inhibitor of the JAK family. JAKs are enzymes inside the cell that pass on signals coming from cytokine or growth factor-receptor interactions on the cell membrane. JAK1 is important in mediating inflammatory cytokine signals, JAK2 in mediating myelopoiesis and erythropoiesis, and JAK3 plays critical roles in immune homeostasis and lymphopoiesis. Along this signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate activity inside the cell, including gene expression. Filgotinib modulates these pathways by preventing the phosphorylation and activation of STATs. In biochemical assays, filgotinib preferentially inhibited the activity of JAK1, and it showed >5-fold higher potency for JAK1 over JAK2, JAK3 and TYK2.

Pregnancy & Breastfeeding

Use in pregnancy: There's little or no data on the use of filgotinib in pregnant women. Studies in animals have shown reproductive toxicity. Going by those animal findings, filgotinib may cause fetal harm, so it is contraindicated during pregnancy.

Women of childbearing potential / Contraception: Women who could become pregnant have to use effective contraception during treatment with filgotinib and for at least 1 week after stopping it.

Lactation: It is unknown whether filgotinib passes into human milk. A risk to breastfed newborns and infants can't be ruled out, so filgotinib should not be used during breast-feeding.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: For rheumatoid arthritis, the recommended dose of Filgotinib is one 200 mg tablet once a day. For ulcerative colitis, the recommended dose is also 200 mg once daily. If a patient has shown no therapeutic benefit after 22 weeks of treatment, Filgotinibib should be stopped. Adults at higher risk of venous thromboembolism, major adverse cardiovascular events and malignancy should take 100 mg once daily as maintenance treatment. If the disease flares, the dose may be raised to 200 mg once daily. For long term treatment, use the lowest effective dose.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.